6533b7d7fe1ef96bd1267756

RESEARCH PRODUCT

Comparison of clinical and metabolic effects of pasireotide and pituitary surgery in Cushing disease

V. GuarnottaA. CiresiG. PizzolantiC. Giordano

subject

pasireotide cushing diseaseSettore MED/13 - Endocrinologia

description

Pituitary surgery represents the first-line treatment for most patients with Cushing’s disease (CD). In the case of surgery failure, additional treatment options are required. Pasireotide has shown favourable results in the first-line treatment of patients with CD, who are not candidates for surgery or in the second-line when surgery has failed. The aim of the current study is to compare the effects of surgery and pasireotide treatment in a cohort of patients with CD, and to evaluate the differences in response rate in terms of hormonal and clinical control, and improvement of metabolic complications.

yearjournalcountryeditionlanguage
2017-01-06
http://hdl.handle.net/10447/236204